Baxter, Claris seek $625M deal approval with remedies
July 24, 2017
Biotechnology | Ahmedabad, India | Corporate Acquisition
Baxter International and Claris Lifesciences have agreed to divest two types of pharmaceutical products to settle US regulatory concerns that Baxter’s proposed $625 million acquisition of Claris’ injectable drugs business would hurt consumers by reducing competition among suppliers of generics. Claris will divest its rights to fluconazole in saline intravenous bags and milrinone in dextrose intravenous bags to Renaissance Lakewood. Baxter, meanwhile, will help Renaissance establish its manufacturing capabilities and secure regulatory approvals for the treatments.